BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 36814910)

  • 1. Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma.
    Gao B; Wang Y; Li C; Lu S
    Front Immunol; 2023; 14():1114717. PubMed ID: 36814910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
    Gao B; Wang Y; Lu S
    Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a prognostic and therapeutic immune signature associated with hepatocellular carcinoma.
    Peng Y; Liu C; Li M; Li W; Zhang M; Jiang X; Chang Y; Liu L; Wang F; Zhao Q
    Cancer Cell Int; 2021 Feb; 21(1):98. PubMed ID: 33568167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction of a Novel LncRNA Signature Related to Genomic Instability to Predict the Prognosis and Immune Activity of Patients With Hepatocellular Carcinoma.
    Zhu J; Huang Q; Liu S; Peng X; Xue J; Feng T; Huang W; Chen Z; Lai K; Ji Y; Wang M; Yuan R
    Front Immunol; 2022; 13():856186. PubMed ID: 35479067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A T-cell-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma based on transcriptomics and single-cell sequencing.
    Chen X; Peng C; Chen Y; Ding B; Liu S; Song Y; Li Y; Sun B; Yang R
    BMC Bioinformatics; 2023 May; 24(1):216. PubMed ID: 37231356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosstalk of cuproptosis-related prognostic signature and competing endogenous RNAs regulation in hepatocellular carcinoma.
    Zhu J; Wang J; Liu H; Lei T; Yang J; Lan S; Jian H; Fang H; Zhang Y; Ren K; Zhong F
    Aging (Albany NY); 2023 Dec; 15(23):13901-13919. PubMed ID: 38078880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
    Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
    Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Prognostic and Immunological Analysis of a New Three-Gene Signature in Hepatocellular Carcinoma.
    Liu J; Lu J; Li W
    Stem Cells Int; 2021; 2021():5546032. PubMed ID: 34188686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma.
    Xiong X; Song Q; Jing M; Yan W
    Genet Res (Camb); 2023; 2023():6879022. PubMed ID: 37313428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
    Jin C; Zhao JS; Huang XQ; Yang XZ; Niu FY; Lin JR; Ma L; Shi YX; Li XS; Jiang P; Gao S; Li F; Song Y
    Hepatol Int; 2022 Oct; 16(5):1220-1233. PubMed ID: 35947245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma.
    Zhang Y; Pang S; Sun B; Zhang M; Jiao X; Lai L; Qian Y; Yang N; Yang W
    Front Oncol; 2022; 12():884066. PubMed ID: 35912257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of cancer-associated fibroblasts signature for predicting the prognosis and immunotherapy response in hepatocellular carcinoma.
    Ye J; Tian W; Zheng B; Zeng T
    Medicine (Baltimore); 2023 Nov; 102(45):e35938. PubMed ID: 37960718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis
    Chi H; Zhao S; Yang J; Gao X; Peng G; Zhang J; Xie X; Song G; Xu K; Xia Z; Chen S; Zhao J
    Front Immunol; 2023; 14():1137025. PubMed ID: 37006257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data.
    Yu L; Shen N; Shi Y; Shi X; Fu X; Li S; Zhu B; Yu W; Zhang Y
    Front Immunol; 2022; 13():1009789. PubMed ID: 36211448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of metabolic models for predicting survival and immune status of hepatocellular carcinoma patients.
    Li X; Gu M; Hu Q; Weng Y; Cai X
    Adv Clin Exp Med; 2023 Dec; 32(12):1423-1439. PubMed ID: 37166013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
    Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
    Front Immunol; 2022; 13():994019. PubMed ID: 36177006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel prognostic signature based on immunogenic cell death score predicts outcomes and response to transcatheter arterial chemoembolization and immunotherapy in hepatocellular carcinoma.
    Zhang Y; Yang J; Xie S; Chen H; Zhong J; Lin X; Yu Z; Xia J
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11411-11429. PubMed ID: 37382674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.